Aurinia Pharmaceuticals Inc.

AUPH
$15.90 (+ $0.35 + 2.25%)
Last updated: 2026-05-20 22:43 UTC
AUPH Metrics
Exchange
🇺🇸 NASDAQ XNMS
Nasdaq/NMS (Global Market)United StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINCA05156V1022
Market Price15.9
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E Ratio28.95
EPS0.56
Market Cap$2.1B
Book Value2.77
Price to Book5.844
Beta1.44
52w High16.54
52w Low6.55
Next Earnings DateN/A

Aurinia Pharmaceuticals Inc. trades under ticker AUPH on NASDAQ as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN CA05156V1022.

About the Company
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Price History